Extended-Release Levetiracetam Therapy for At-Risk Cognitive Decline

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for effective clinical and therapeutic measures to prevent or slow the progression of cognitive impairment or reduce the rate of cognitive decline in individuals who display normal cognitive performance but are at risk due to genetic or biofluid biomarkers associated with conditions like Alzheimer's disease, as no FDA-approved preventive therapies currently exist for this group.

Innovation Solution

Administering levetiracetam, brivaracetam, or seletracetam, or their pharmaceutically acceptable salts, in combination with a GABAA α5 receptor agonist, to individuals with risk factors such as genetic variants or biofluid biomarkers, using extended release formulations to maintain steady plasma concentrations over an extended period.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If preventive therapy is administered to subjects with normal cognitive performance but at risk for cognitive decline, then cognitive decline prevention is improved, but the lack of FDA-approved therapies limits available options

Engineering Contradiction:

Improvecognitive decline preventionVSAvoidtherapeutic options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies preliminary action by administering levetiracetam, brivaracetam, or seletracetam to subjects who currently display normal cognitive performance but have identified risk factors (genetic variants, biomarkers, or altered hippocampal functional connectivity). The therapy is initiated before cognitive decline occurs, with the goal of preventing or slowing the progression of cognitive impairment in at-risk individuals.

Inventive Principle:

Principle #10Preliminary action

2Reliability

If standard release formulations are used, then manufacturing simplicity is maintained, but sustained therapeutic effects are reduced

Engineering Contradiction:

Improvesustained therapeutic effectsVSAvoidformulation complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent specifies that extended release formulations of levetiracetam, brivaracetam, or seletracetam are administered to maintain steady plasma concentrations over an extended period. This preliminary preparation of the formulation ensures sustained therapeutic effects by delaying and prolonging drug release, thereby maintaining effective drug levels in the bloodstream over time.

Inventive Principle:

Principle #10Preliminary action

3Measurement precision

If multiple risk factors are considered for therapy selection, then treatment precision is improved, but assessment complexity increases

Engineering Contradiction:

Improverisk assessment precisionVSAvoidassessment complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent identifies specific parameters for risk assessment including genetic variants (ABCA7, CLU, CR1, PICALM, PLD3, TREM2, SORL1), biofluid biomarkers (p-tau, t-tau, amyloid β42), and altered hippocampal functional connectivity. By measuring and evaluating these specific parameters, the patent enables precise identification of subjects at risk for cognitive decline, allowing for targeted therapy selection based on their risk profile.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively prevents or slows cognitive decline by targeting underlying risk factors, providing sustained therapeutic effects through controlled release formulations.

Implementation Method 1

a GABAA α5 receptor agonist or a pharmaceutically acceptable salt, hydrate, solvate, isomer, or polymorph thereof

Methodology Applied

Scientific EffectGABAA α5 receptor agonist activity:

Implementation Method 2

using extended release formulations to maintain steady plasma concentrations over an extended period

Methodology Applied

Scientific EffectControlled release:

Data Source

PatentUS20250228820A1Methods for preventing or slowing the progression of cognitive decline or impairment in subjects displaying normal cognitive performance

Publication Date: 2025.07.17 AGENEBIO INC

AI summary

Methods for preventing or slowing the progression of cognitive impairment or preventing the development or reducing the rate of cognitive decline in a subject displaying or presenting with cognitive performance within the normal range for the subject's age. The methods comprise administering to the subject one or more of levetiracetam, brivaracetam or seletracetam, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising levetiracetam, brivaracetam or seletracetam or pharmaceutical salt thereof and a pharmaceutically acceptable carrier, a GABAA α5 receptor agonist or a pharmaceutically acceptable salt, hydrate, solvate, isomer, or polymorph thereof, a pharmaceutical composition comprising a GABAA α5 receptor agonist or a pharmaceutically acceptable salt, hydrate, solvate, isomer, or polymorph thereof, and a pharmaceutically acceptable carrier, or a combination or a composition comprising the levetiracetam, brivaracetam or seletracetam or pharmaceutical salt thereof and the GABAA α5 receptor agonist or a pharmaceutically acceptable salt, hydrate, solvate, isomer, or polymorph. In some embodiments, the subjects have one or more risk factors that are predictive for or associated with the development or progression of cognitive impairment or decline.